Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Waverley Pharma Inc V.WAVE

Healthcare Biotechnology
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution... see more

TSXV:WAVE - Post Discussion

Waverley Pharma Inc > News!!
View:
Post by Wapiti1000 on Jan 18, 2021 10:47am

News!!

https://apple.news/AiU_UGIvvTkK3Em8vr7_kJQWINNIPEG, MB, Jan. 18, 2021 /CNW/ - Waverley Pharma Inc. (TSXV: WAVE) ("Waverley Pharma" or the "Company"), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly owned Irish subsidiary, Waverley Pharma Europe Limited ("WPEL"), has been awarded exclusive distribution rights for capecitabine by the National Health Services of Scotland ("NHS Scotland"). 

The awarded NHS Scotland tender is projected to increase the Company's revenue by approximately £200,000 on an annual basis. This opportunity also represents WPEL's first successful tender proposal for capecitabine in the NHS Scotland region. The tender will commence on February 1, 2021 and has a duration of two years. WPEL currently has awarded tenders for capecitabine in both Wales and England with each region's respective National Health Services organization. 

"Waverley Pharma is excited to announce our fifth successful tender award since 2019, which affirms our commitment to expanding our oncology presence in the UK and EU markets," stated Larry Thiessen, President and Chief Executive Officer.

 
Be the first to comment on this post
Waverley Pharma Inc